Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1824732rdf:typepubmed:Citationlld:pubmed
pubmed-article:1824732lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:1824732lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:1824732lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1824732lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:1824732lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:1824732lifeskim:mentionsumls-concept:C0033572lld:lifeskim
pubmed-article:1824732lifeskim:mentionsumls-concept:C0029189lld:lifeskim
pubmed-article:1824732lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:1824732lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:1824732lifeskim:mentionsumls-concept:C0149473lld:lifeskim
pubmed-article:1824732pubmed:issue1lld:pubmed
pubmed-article:1824732pubmed:dateCreated1991-2-12lld:pubmed
pubmed-article:1824732pubmed:abstractTextWe report preliminary results for the first 164 patients enrolled in a multicenter study comparing the endocrine effects, efficacy, and safety of 3.6 mg of goserelin acetate (Zoladex) and orchiectomy in patients with Stage D2 prostate cancer. Eighty-one patients were randomly allocated to receive Zoladex and 83 to orchiectomy. The median follow-up time for all patients was two hundred ten days. Median serum levels of testosterone were reduced to castrate levels (less than 50 ng/dL) within four weeks in both groups and remained suppressed for up to sixty weeks. An objective response according to modified criteria of the National Prostatic Cancer Project was observed in 81 percent and 78 percent of patients in the Zoladex and orchiectomy groups, respectively. There were no statistically significant differences between treatment groups in the distributions of time to treatment failure or time to disease progression. The most commonly reported adverse events in both treatment groups were hot flashes, cancer-related pain, unspecified pain, and urinary symptoms. These results suggest that Zoladex may offer an alternative to orchiectomy in the treatment of advanced prostate cancer.lld:pubmed
pubmed-article:1824732pubmed:languageenglld:pubmed
pubmed-article:1824732pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1824732pubmed:citationSubsetIMlld:pubmed
pubmed-article:1824732pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1824732pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1824732pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1824732pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1824732pubmed:statusMEDLINElld:pubmed
pubmed-article:1824732pubmed:monthJanlld:pubmed
pubmed-article:1824732pubmed:issn0090-4295lld:pubmed
pubmed-article:1824732pubmed:authorpubmed-author:PANK FKFlld:pubmed
pubmed-article:1824732pubmed:authorpubmed-author:ScottMMlld:pubmed
pubmed-article:1824732pubmed:authorpubmed-author:BlockN LNLlld:pubmed
pubmed-article:1824732pubmed:authorpubmed-author:SolowayM SMSlld:pubmed
pubmed-article:1824732pubmed:authorpubmed-author:VogelzangN...lld:pubmed
pubmed-article:1824732pubmed:authorpubmed-author:SchellhammerP...lld:pubmed
pubmed-article:1824732pubmed:authorpubmed-author:SmithJ AJAJrlld:pubmed
pubmed-article:1824732pubmed:authorpubmed-author:ChodakGGlld:pubmed
pubmed-article:1824732pubmed:authorpubmed-author:KennealeyGGlld:pubmed
pubmed-article:1824732pubmed:issnTypePrintlld:pubmed
pubmed-article:1824732pubmed:volume37lld:pubmed
pubmed-article:1824732pubmed:ownerNLMlld:pubmed
pubmed-article:1824732pubmed:authorsCompleteYlld:pubmed
pubmed-article:1824732pubmed:pagination46-51lld:pubmed
pubmed-article:1824732pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:meshHeadingpubmed-meshheading:1824732-...lld:pubmed
pubmed-article:1824732pubmed:year1991lld:pubmed
pubmed-article:1824732pubmed:articleTitleZoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.lld:pubmed
pubmed-article:1824732pubmed:affiliationUniversity of Tennessee Center for the Health Sciences, Memphis.lld:pubmed
pubmed-article:1824732pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1824732pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1824732pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1824732pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:1824732pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:1824732pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1824732lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1824732lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1824732lld:pubmed